Meta AnalysisID 7256
评估糖尿病神经病变的药物干预：一项网状Meta分析
CRD42023454183
What is the comparative efficacy of pharmacological interventions for diabetic neuropathy in providing freedom from pain in patients?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7256
- Evidence Id
- 15814
- Core Evidence Id
- 15814
- Source Meta Analysis Id
- 7240
- Herb2 Meta Analysis Id
- HBMA007240
- Crd Id
- CRD42023454183
- Title
- Evaluating Pharmacological Interventions for Diabetic Neuropathy: A Network Meta-Analysis
- Review Question
- What is the comparative efficacy of pharmacological interventions for diabetic neuropathy in providing freedom from pain in patients?
- Study Type Included
- We will include only randomized control trials (RCTs) with a comparator population to assess the efficacy of all pharmacological treatments for diabetic neuropathic pain
- Condition Being Studied
- Pharmacological interventions used to manage diabetic neuropathy. Diabetic neuropathy is a frequent debilitating complication of diabetes mellitus that significantly impacts the quality of life (QoL) and functional abilities of the patient. We aim to integrate the available evidence by a network meta-analysis incorporating the recent studies and utilizing enhanced statistical methods to provide an evidence-based recommendation for guiding clinical decision making on the most effective and safe pharmacological treatments for diabetic neuropathies and optimize patient outcomes.
- Participant
- Patients experiencing pain attributed to diabetic neuropathy.
- Animal
- Human Disease Modelled
- Intervention
- 1) Antidepressants a) SNRIs: Duloxetine Venlafaxine Desvenlafaxine b) TCAs: Amitriptyline Nortriptyline Desipramine Imipramine 2) Anticonvulsants (mostly GABA antiseizure medications) Pregabalin Gabapentin Carbamazepine Lacosamide Topiramate 3) Topical analgesics Ketamine, Esketamine, Lidocaine, Pirfenidone, Cannabidiol, Lignocaine OR Capsaicin, Clonidine, NGX-4010, Pregabalin, Pirfenidone 4) Opioids Difelikefalin, tapentadol, oxycodone, fentanyl, morphine, buprenorphine, tramadol, codeine, hydrocodone 5) Aldose Reductase Inhibitors 6) Antiarrhythmic drugs: Mexiletine, Quinidine 7) Other Drugs: Palmitoylethanolamide Xiaoketongbi Formula vs Pregabalin Melatonin Mesenchymal stem cell-like product (PDA-002) vs Placebo Naltrexone Trazodone vs Placebo Teneligliptin Tocovid vs Placebo Topiramate Dextromethorphan coadministered with Quinidine Topical 5% ketamine cream vs placebo 0.1% topical clonidine gel vs placebo Isosorbide dinitrate spray Botulinum toxin type A Alpha lipoic acid Tapentadol extended release An attempt will be made to include all drugs further identified from literature review on pharmacological interventions in diabetic neuropathy.
- Comparator Control
- Placebo Neurological controls Other classes of drugs
- Main Outcome
- The primary outcome of this updated network meta-analysis is to assess pain relief in patients with painful diabetic neuropathy. Pain relief can be evaluated through two measures: 1. Dichotomous Outcome - determining the proportion of patients experiencing a pain decrease and 2. Continuous Outcome - utilizing the standardized mean difference (SMD) on a pain scale to evaluate pain relief. To ensure a comprehensive approach, we will conduct a thorough screening of randomized controlled trials (RCTs) and identify other clinically relevant outcomes of measurement. Measures of effect Proportion variable - Risk ratio/Hazard ratio Continuous variable - Mean difference between populations
- Outcome Measure
- Additional Outcome
- Adverse Effects: The study evaluates and reports the most frequent adverse effects and treatment intolerance of the analyzed medications used to treat painful diabetic neuropathy compared to placebo or other neurological controls. Long-term Analgesic Efficacy: The study will also assess the long-term analgesic effect of some drugs. However, data on the long-term efficacy of other drugs will be limited due to a lack of studies with extended follow-up periods. To ensure a comprehensive approach, we will conduct a thorough screening of randomized controlled trials (RCTs) and identify other clinically relevant outcomes of measurement.
- Study Method
- Intervention, Meta-analysis, Network meta-analysis, Synthesis of qualitative studies, Systematic review
- Keyword
- Diabetes Mellitus; Diabetic Neuropathies; Freedom; Humans; Network Meta-Analysis; Pain; Patients
- Contact
- Dr. Mainak Bardhan [email protected]
- Organisational Affiliation
- Miami Cancer Institute, Baptist Health South Florida, USA King George's Medical University, Lucknow, India Bukovinian State Medical University, Chernivtsi, Ukraine All India Institute of Medical Sciences, Jodhpur, India Nepalese Army Institute of Health Sciences, Nepal Medical College, Kolkata, India Directorate of Factories, Department of Labour, Government of West Bengal, India Department of Neurology, Yale School of Medicine, USA Department of Statistics and Data Science, Weill Cornell Medical College, Cornell University, USA Nepalese Army Institute of Health Sciences, Nepal
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- India, Nepal, Ukraine, United States of America
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-08-13
- Registration Date
- 2023-08-24
- Anticipated Start Date
- 2023-08-01
- Anticipated Completion Date
- 2024-09-15
- Title Cn
- 评估糖尿病神经病变的药物干预：一项网状Meta分析
- Title En
- Evaluating Pharmacological Interventions for Diabetic Neuropathy: A Network Meta-Analysis
- Bilingual Status
- complete